Starting in 2026, NIBRT training will be piloted at Heartland BioWorks’ Indianapolis headquarters with hands-on training beginning in 2027.

Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, in a deal designed to expand the buyer’s cancer pipeline with Halda’s precision oncology candidates, led by a ...

Tumors trigger T-cell exhaustion through a TSP-1–CD47 signaling pathway. Blocking it can restore immune strength and improve cancer treatment.

The Fugaku supercomputer builds a highly detailed virtual mouse cortex with millions of neurons enabling unprecedented ...

AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.

Prophylactic HPV vaccines prevent infection but not existing disease. A nasal nanogel vaccine shows preclinical promise for ...

Microrobots could be precisely directed, under clinical conditions, by integrating systems for navigation, therapeutic ...

When a German manufacturer of blow-fill-seal (BFS) equipment for sterile pharmaceutical products looked to expand into the United States three decades ago, it initially considered a California site, ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...

Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral portfolio with a Phase III drug designed ...

Animal testing is costly, slow, and poorly predictive. ORIVA offers a human-relevant alternative with the potential to change that.

Engineered human stomach organoids, transplanted into mice, produced insulin-secreting cells, offering a potential new ...